Denali Therapeutics Inc. (DNLI)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 336 | 49 | 108 | 331 | 0 | 0 | 4 | - |
| Operating profit | $m | -555 | -543 | ||||||
| Net profit | $m | 71 | -291 | -326 | -145 | -423 | -513 | -511 | -398 |
| EPS reported | $ | -2.97 | -2.84 | ||||||
| Operating cashflow per share | $ | -2.35 | -2.32 | ||||||
| Capex per share | $ | 0.05 | 0.02 | ||||||
| FCF per share | $ | -2.41 | -2.34 | ||||||
| Free cash flow | $m | -422 | -437 | ||||||
| Net debt | $m | -868 | -710 | ||||||
| Book value equity | $m | 1,014 | 835 | ||||||
| Book value per share | $ | 5.78 | 4.46 | ||||||
| Number of shares | m | 175.46 | 187.31 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 2.86 | 3.47 | ||||||
| P/S LTM | x | 0.00 | 803.78 | ||||||
| P/FCF LTM | x | -6.86 | -6.62 | ||||||
| EV/EBITDA LTM | x | -5.48 | -5.49 | ||||||
| EV/Sales LTM | x | 0.00 | 1,008.60 | ||||||
| Earnings Yield LTM | % | -17.69% | -11.38% | ||||||
| FCF Yield | % | -14.57% | -15.10% | ||||||
| Quality | |||||||||
| ROE | % | -50.56% | -55.27% | ||||||
| ROIC | % | -52.59% | -50.82% | ||||||
| Operating margin | % | 0.00% | -150.58% | ||||||
| Gross margin | % | 0.00% | -61.04% | ||||||
| FCF/Sales | % | - | -12138.1% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -11.48 | -15.90 | ||||||
| Net Debt/EBITDA | x | 0.34 | 0.35 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -0.86 | -0.85 | ||||||
| Gross debt/equity | x | 0.04 | 0.03 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free